Affymax Lays Out Hematide Phase III Development Plan For Anemia
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA allows firm to compare the novel artificial peptide-based ESA head-to-head with currently marketed recombinant products, a move that may bode well for EPOs in upcoming Cardio Renal panel review.